PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease.
Saved in:
| Title: | PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease. |
|---|---|
| Authors: | Lu C; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Yan HH; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zhang CY; Department of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, China., Chen SY; Tenth Affiliated Hospital, Southern Medical University (Dongguan people's hospital), Dongguan, China., Li YS; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Wang BC; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Xu CR; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Tu HY; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zhong WZ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zhang XC; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Feng WN; Department of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, China., Jiang GM; Tenth Affiliated Hospital, Southern Medical University (Dongguan people's hospital), Dongguan, China., Yang JJ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. Electronic address: yangjinji@gdph.org.cn. |
| Source: | Clinical lung cancer [Clin Lung Cancer] 2025 Jun; Vol. 26 (4), pp. 263-266. Date of Electronic Publication: 2024 Dec 04. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39721825 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Lu+C%22">Lu C</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Yan+HH%22">Yan HH</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhang+CY%22">Zhang CY</searchLink>; Department of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, China.<br /><searchLink fieldCode="AU" term="%22Chen+SY%22">Chen SY</searchLink>; Tenth Affiliated Hospital, Southern Medical University (Dongguan people's hospital), Dongguan, China.<br /><searchLink fieldCode="AU" term="%22Li+YS%22">Li YS</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wang+BC%22">Wang BC</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Xu+CR%22">Xu CR</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Tu+HY%22">Tu HY</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhong+WZ%22">Zhong WZ</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhou+Q%22">Zhou Q</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhang+XC%22">Zhang XC</searchLink>; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Wu+YL%22">Wu YL</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Feng+WN%22">Feng WN</searchLink>; Department of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, China.<br /><searchLink fieldCode="AU" term="%22Jiang+GM%22">Jiang GM</searchLink>; Tenth Affiliated Hospital, Southern Medical University (Dongguan people's hospital), Dongguan, China.<br /><searchLink fieldCode="AU" term="%22Yang+JJ%22">Yang JJ</searchLink>; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. Electronic address: yangjinji@gdph.org.cn. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100893225%22">Clinical lung cancer</searchLink> [Clin Lung Cancer] 2025 Jun; Vol. 26 (4), pp. 263-266. <i>Date of Electronic Publication: </i>2024 Dec 04. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial Protocol; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100893225 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0690 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215257304%22">15257304 </searchLink><i>NLM ISO Abbreviation: </i>Clin Lung Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39721825 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.cllc.2024.12.002 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 263 Titles: – TitleFull: PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lu C – PersonEntity: Name: NameFull: Yan HH – PersonEntity: Name: NameFull: Zhang CY – PersonEntity: Name: NameFull: Chen SY – PersonEntity: Name: NameFull: Li YS – PersonEntity: Name: NameFull: Wang BC – PersonEntity: Name: NameFull: Xu CR – PersonEntity: Name: NameFull: Tu HY – PersonEntity: Name: NameFull: Zhong WZ – PersonEntity: Name: NameFull: Zhou Q – PersonEntity: Name: NameFull: Zhang XC – PersonEntity: Name: NameFull: Wu YL – PersonEntity: Name: NameFull: Feng WN – PersonEntity: Name: NameFull: Jiang GM – PersonEntity: Name: NameFull: Yang JJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2025 Jun Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1938-0690 Numbering: – Type: volume Value: 26 – Type: issue Value: 4 Titles: – TitleFull: Clinical lung cancer Type: main |
| ResultId | 1 |
